A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics

By Stephanie D. Steichen, Mary E. Caldorera-Moore, Nicholas A. Peppas. European Journal of Pharmaceutical Sciences, 2012

710 citations recorded by the source corpus.

The tumor microenvironment provides unique challenges for the delivery of chemotherapeutic agents in doses that are effective while ensuring minimal systemic toxicity. The primary limitation of current therapeutics is a lack of specificity in delivery, as they target healthy and cancerous cells alike. The development of nanoscale carriers capable of delivering cancer therapies has the potential to overcome both systemic and tumor barriers and provide specific, targeted delivery. This review seeks to provide an overview of available nanoscale drug carriers by exploring the wide variety of developed nanostructures and the most commonly used moieties for targeted delivery. Additionally, the use of nanoscale carriers will be motivated by examining tumor physiology and the specific barriers present within both the tumor microenvironment and systemic delivery.

Subfields: Biomaterials, Biomedical Engineering

View Paper: https://www.semanticscholar.org/paper/1a21fe8f704c8cf21255ee4fdb8fb8942154ad14

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. N. Bertrand
2. Xiaoyang Xu
3. O. Farokhzad
4. Xueqing Zhang

In Biomedical Engineering

1. N. Bertrand
2. Xiaoyang Xu
3. O. Farokhzad
4. Xueqing Zhang

Citations in the corpus

• Cancer Nanomedicine: From Targeted Delivery to Combination Therapy (2015, background): “For example, the increasing availability of monoclonal antibodies has fostered interest in antibody-functionalized nanomedicines for many years [61,62].”